NOT A HOTEL Opens Tokyo Office in Harumi, Featuring The NIGO Lounge
NOT A HOTELhas announced the opening of its new multi-purpose NOT A HOTEL OFFICE in Harumi, Tokyo. This expansive, warehouse-like space will serve as the company's official headquarters, despite its remote-work-first philosophy. Designed by NOT A HOTEL ARCHITECTS, the office layout includes diverse workspaces, event areas, and meeting rooms, all crafted to embody the company's distinct worldview.
The new office serves as both a laboratory and a creative hub where NOT A HOTEL can experiment with novel work methods and envision future products and services. Its design promotes flexible adaptation, encouraging all members to collaborate and innovate. A standout feature of the new headquarters is The NIGO Lounge, an exclusive event and workspace produced by internationally renowned creative director NIGO®. This private lounge is reserved solely for owners of NOT A HOTEL properties, offering a unique, limited experience for one group per day. Equipped with state-of-the-art smokeless yakiniku grills and back kitchens for meal preparation, it's designed to host intimate dinners and parties.
Inside The NIGO Lounge,NIGO's personal design sensibilities are evident. A massive storage wall, consisting of 284 units of the Swiss USM Haller modular furniture system (a long-time favorite of NIGO's), is stacked high in a U-shape. This meticulous organization provides both functionality and a striking visual backdrop. The NOT A HOTEL OFFICE also prominently features an authentic Jean Prouvé 6×6 Demountable House from 1944, imported directly from France. This historic structure, filled with vintage French modernist furniture, reflects NOT A HOTEL's minimalist design philosophy and perfectly captures their ethos of 'living anywhere.'
The main common area boasts a remarkable 15-meter-long wooden table, serving as a central point for both office work and events.Cassina's black block stools, a collaboration withVirgil Abloh, are arranged around this imposing table, adding a touch of contemporary design. This 40-meter-deep space is designed to foster spontaneous interaction, allowing diverse ideas and people to converge. The office also includes 36 free-address desks and four quiet pods, combining openness with functionality. A meeting space with a dark gray kitchen, equipped with the same high-end appliances and cutlery as NOT A HOTEL properties, rounds out the dynamic environment.
Furthermore, the office acts as a display for NIGO's personal collection of rare items and features PRATONE lounge chairs, blending a functional workspace with elements of a curated art gallery. This innovative office design truly embodies NOT A HOTEL's forward-thinking approach to work and hospitality.
NOT A HOTEL OFFICECROSS DOCK HARUMI, 1FHarumi 4-7-4Chūō-ku, Tokyo-to104-0053
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
4 hours ago
- Business Insider
MRNA Earnings: Moderna Stock Slumps 10% on Lower Covid Vaccine Demand
Shares in drug giant Moderna (MRNA) plummeted nearly 10% today after it reported a drop in Q2 sales. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The company reported earnings for the period of -$2.13, beating expectations of -$3.03 but also recorded a 41.1% drop in year-over-year sales to $142 million. However, that still beat forecasts of $128.3 million. Sentiment Hit Investor sentiment was also hit by the company dropping its revenue guidance for the full year to $1.85 billion at the midpoint from $2 billion, a 7.5% decrease. It blamed the 'timing of shipments.' The decline was primarily driven by lower Spikevax COVID vaccine sales, which totaled $114 million in the quarter. Moderna said demand is expected to be concentrated in the second half of the year, aligning with the fall and winter seasons as the vaccine continues to transition into a seasonal respiratory product. It also reported 'negligible' RSV vaccine mRESVIA® sales in the second quarter of 2025. The figures continue Moderna's difficult year in comparison with its peers – see below. 'In the last three months, we advanced our pipeline with positive Phase 3 flu vaccine efficacy data and expanded our commercial portfolio with three new U.S. FDA approvals to drive future sales growth,' said Stéphane Bancel, Chief Executive Officer of Moderna. 'Looking forward, we have important catalysts over the next six months across our infectious disease and oncology programs that will help us deliver on the promise of our mRNA platform for patients.' Future Hopes This includes Intismeran autogene, a personalized cancer therapy which is being developed in collaboration with Merck (MRK). This includes two non-small cell lung cancer Phase 3 studies and Phase 2 studies for high-risk muscle invasive and high-risk non-muscle invasive bladder cancer. Cost of sales for 2025 is expected to be approximately $1.2 billion. Full-year 2025 research and development expenses are anticipated to be $3.6 to $3.8 billion, lowered from previous expectations of approximately $4.1 billion. Year-end cash and investments for 2025 are projected to be approximately $6 billion. Recently, Moderna announced an organizational restructuring that will reduce its global workforce by approximately 10%. The company anticipates a total headcount of less than 5,000 by the end of the year. Better news came today for the group after Pfizer (PFE) and its German partner BioNTech (BNTX) lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents at London's Court of Appeal.
Business Wire
10 hours ago
- Business Wire
Align Technology President and CEO Joe Hogan Personally Purchases $1 Million of Align's Common Stock
TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. ('Align') (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign ® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that Joe Hogan, Align Technology president and CEO, has personally purchased approximately $1 million of Align's common stock. Since his last sale of Align common stock in 2021, Mr. Hogan has purchased approximately $8 million of Align common stock 1. 'This purchase reflects my continuing confidence in the long-term value of Align and our commitment to increasing shareholder value by balancing investments to drive growth and continuing to invest with discipline in the areas that will define our future,' said Joe Hogan, president and CEO. 'We are excited about our next-generation technologies and treatment platforms that meet today's patient expectations for fast, effective, and personalized treatment while also providing value and growth opportunities for our doctor customers. We believe that these innovations are not only improving outcomes in Invisalign practices but also expanding our addressable market and strengthening our competitive differentiation.' Continued Hogan, 'While we believe that the macroeconomic uncertainty will likely persist into the near future, we are confident in our ability to adapt and lead. Our long-term strategic initiatives and opportunities remain intact, as does our commitment to focused execution on transforming treatment for doctors and patients.' 1 Valued based on the purchase price of Align common stock at the time of each purchase. About Align Technology Align Technology designs and manufactures the Invisalign ® System, the most advanced clear aligner system in the world, iTero™ intraoral scanners and services, and exocad™ CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for over 286.4 thousand doctor customers and are key to accessing Align's 600 million consumer market opportunity worldwide. Over the past 28 years, Align has helped doctors treat over 20.8 million patients with the Invisalign System and is driving the evolution in digital dentistry through the Align™ Digital Platform, our integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and lab/partners. Visit for more information. For additional information about the Invisalign System or to find an Invisalign doctor in your area, please visit For additional information about the iTero digital scanning system, please visit For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit Invisalign, iTero, exocad, Align, Align Digital Platform, and iTero Lumina are trademarks of Align Technology, Inc.
Yahoo
11 hours ago
- Yahoo
Mistral in talks with VC firms, MGX to raise funds at $10 billion valuation, FT reports
(Reuters) -French artificial intelligence startup Mistral is in talks with investors, venture capital firms and Abu Dhabi's MGX to raise $1 billion at a valuation of $10 billion, the Financial Times reported on Friday, citing people familiar with the matter. The company launched in June Europe's first AI reasoning model, which uses logical thinking to create a response, as it tries to keep pace with American and Chinese rivals at the forefront of AI development. The funding would accelerate the commercial rollout of Mistral's Le Chat chatbot and support continued development of its large language models, the report said. MGX and Mistral did not immediately respond to Reuters requests for comment. The startup raised 600 million euros in a Series B funding round that valued the company at 5.8 billion euros last year. Industry observers consider Mistral as Europe's best-positioned AI company to rival Silicon Valley leaders, though the French firm has yet to achieve comparable market traction or revenue scale. Mistral counts Nvidia, Andreessen Horowitz and Lightspeed Venture Partners among its investors. Sign in to access your portfolio
